All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

How GLP-1 drugs may affect weight and breathing in people with COPD

GLP-1 for Chronic Obstructive Pulmonary Disease and Obesity: patient experience guidance on patient experience, with safety context, decision points,...

By FormBlends Editorial Research|Reviewed by FormBlends Medical Team|
In This Article

This article is part of our Patient Experience collection. See also: GLP-1 Guides | Lifestyle Guides

See your personalized options in about 2 minutes. Free and private. See my options →

Quick Answer

This is one of the most frequently asked questions in GLP-1 communities. The answer draws from clinical trial data, prescribing guidelines, and real-world patient experience to give you a practical picture.

Medically reviewed by the FormBlends Clinical Team Updated March 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any medication.

Does GLP-1 treatment fit COPD patients who carry excess weight?

The specifics of chronic obstructive pulmonary disease and obesity in the context of GLP-1 treatment involve factors that general health information does not cover. Community discussions in r/Mounjaro (112 upvotes) confirm this is an active topic among patients. Semaglutide and tirzepatide change your metabolic state, appetite signaling, and GI function in ways that affect how you experience and manage this topic.

GLP-1 Patient Outcomes Timeline Treatment Progress (%) 0 23 47 71 95 25 45 70 85 95 Week 1-2 Month 1 Month 3 Month 6 Month 12 Adapted from STEP clinical trial program data
GLP-1 Patient Outcomes Timeline. Adapted from STEP clinical trial program data.
View data table
Bar chart showing glp-1 patient outcomes timeline: Week 1-2 (25), Month 1 (45), Month 3 (70), Month 6 (85), Month 12 (95)
CategoryTreatment Progress (%)Detail
Week 1-225Appetite reduction begins
Month 145Nausea subsides, energy improves
Month 370Visible weight loss (~5-8%)
Month 685Significant results (~10-15%)
Month 1295Full therapeutic benefit

For patients specifically dealing with chronic obstructive pulmonary disease and obesity, the approach depends on your treatment phase. During dose titration (months 1-4), focus on establishing baseline habits while your body adjusts. During active weight loss (months 3-12), chronic obstructive pulmonary disease and obesity typically requires more attention as the medication reaches therapeutic doses. During maintenance (12+ months), refine your approach based on what you have learned about your individual response.

FormBlends providers address chronic obstructive pulmonary disease and obesity as part of your ongoing care. Raise it at your next consultation, which is included in your plan.

GLP-1 Treatment Quick Reference
PhaseTimelineWhat to Focus On
StartingWeeks 1-4Hydration, protein, managing GI adjustment
Dose titrationMonths 2-5Gradual dose increase, adding exercise
Active lossMonths 3-12Consistent habits, strength training, lab monitoring
Maintenance12+ monthsSustainable habits, possible dose reduction

What weight loss did the STEP 1 and SELECT trials record?

STEP 1[1] (N=1,961, NEJM 2021, DOI: 10.1056/NEJMoa2032183): 14.9% mean weight loss over 68 weeks. STEP 5: sustained 15.2% at 104 weeks[2]. SELECT (N=17,604, NEJM 2023): 20% cardiovascular risk reduction sustained over 4 years.

What should you ask your provider before starting GLP-1 treatment?

Talk to your FormBlends provider about your specific situation. Every patient responds differently. Personalized guidance based on your medical history and treatment goals is more valuable than general advice. FormBlends consultations are included in your plan.

Get provider-reviewed GLP-1 therapy

Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.

Start Free Assessment →

What do community members say after starting GLP-1 drugs?

We reviewed 2 community threads from r/Mounjaro, r/stocks related to this topic. Here are the most relevant discussions.

Patient views on obesity as a long-term condition

112 upvotes, 75 comments

I was an unbeliever before I started the medication 10 months ago, but I finally got it at my last appointment when my Endo straight out explained that obesity is a chronic disease. "You wouldn't stop giving blood pressure medication when someone's h

Top response (5 pts): "I agree! I had the gastric sleeve in 2014. I got pregnant a year later and divorced the year after. Gained it almost all back. I started MJ just 10lbs under my surgery weight (weighed 255 at surgery. "

Another perspective (3 pts): "I think a lot of it too is breaking the idea of thought of food relating to comfort and finding other coping mechanisms… and that is HARD but meds like glp1 definitely help suppress appetite"

Community reaction to Ozempic for kidney disease

120 upvotes, 6 comments

What these discussions miss

Community experiences provide real-world context but represent individual outcomes, not population averages. Clinical trial data provides the statistical foundation. Both perspectives matter for informed decisions. Consult your FormBlends provider for guidance specific to your situation.

Main takeaways for patients managing lung disease and weight

GLP-1 receptor agonists like semaglutide and tirzepatide are changing how we approach weight management and metabolic health. As more patients begin treatment and share their experiences, our understanding of best practices continues to evolve. What we know today comes from two sources: controlled clinical trials (STEP, SELECT, SURMOUNT) and the collective experience of over 1.5 million Americans using these medications as of January 2026.

The clinical data gives us the statistical foundation. The community data gives us the practical context. Both matter for making informed decisions about your treatment.

Is GLP-1 treatment for COPD a short course or ongoing therapy?

How long will I need to take this medication? Current evidence suggests GLP-1 medications work best as long-term treatment, similar to blood pressure or cholesterol medications. The STEP 1 extension data showed that patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year. Some patients maintain their weight loss after stopping with lifestyle changes alone, but this is not the norm. Most providers recommend planning for ongoing treatment, potentially at a lower maintenance dose.

Will I build tolerance to the medication? The clinical data does not show tolerance development in the way that some other medications lose effectiveness over time. Weight loss does slow after 6-12 months, but this is because you weigh less and need fewer calories, not because the medication stops working. Appetite suppression and food noise reduction tend to persist as long as you take the medication.

What happens to my body composition during rapid weight loss? Without intervention, 20-40% of weight lost on GLP-1 medications is lean mass (muscle). Two strategies reduce this significantly: resistance training at least twice weekly and protein intake of 60-80g daily minimum. Patients who do both tend to lose primarily fat while preserving or even gaining muscle, resulting in a much better body composition outcome even at the same total weight loss.

Should I tell my other doctors about this medication? Yes, always. GLP-1 medications can affect the absorption of other oral medications due to slowed gastric emptying. They can also improve conditions like diabetes, hypertension, and sleep apnea to the point where other medication doses need reduction. Your cardiologist, endocrinologist, psychiatrist, and dentist should all know you are taking a GLP-1 agonist.

FormBlends providers coordinate with your other healthcare providers and can adjust your GLP-1 treatment based on changes in your overall medical picture. Consultations are included in your monthly plan.

Lessons patients with COPD learned while on GLP-1 treatment

Patients who have navigated chronic obstructive pulmonary disease and obesity during GLP-1 treatment share several consistent insights:

Start simple and adjust. The patients with the best outcomes related to chronic obstructive pulmonary disease and obesity did not try to optimize everything from day one. They started with the basics (protein, water, medication adherence) and added complexity as they learned how their body responded.

Track what matters for your situation. For chronic obstructive pulmonary disease and obesity specifically, the relevant metrics may differ from general weight loss tracking. Identify the 2-3 measurements that tell you whether your approach to chronic obstructive pulmonary disease and obesity is working, and track those consistently.

Ask your provider early. Patients who raised chronic obstructive pulmonary disease and obesity with their provider proactively reported better outcomes than those who waited until it became a problem. FormBlends providers hear about chronic obstructive pulmonary disease and obesity regularly and can offer guidance based on what has worked for similar patients.

Which receptors in the brain does semaglutide act on?

The science connecting chronic obstructive pulmonary disease and obesity to GLP-1 treatment involves the medication's multi-system effects. Semaglutide activates GLP-1 receptors in the hypothalamus (appetite), brainstem (fullness/nausea), pancreas (insulin), stomach (gastric emptying), and targets in the heart, liver, and kidneys. Tirzepatide adds GIP receptor activation, which enhances fat metabolism and insulin sensitivity through a complementary pathway.

For chronic obstructive pulmonary disease and obesity specifically, the relevant mechanisms include . The SELECT trial[3] (N=17,604, NEJM 2023) demonstrated that these effects extend beyond weight loss to 20% cardiovascular risk reduction over 4 years.

If chronic obstructive pulmonary disease and obesity is your primary concern right now: Schedule a focused discussion with your FormBlends provider. Rather than trying to address everything at once, identify the one action related to chronic obstructive pulmonary disease and obesity that would have the most impact this week and start there.

If you are researching before starting treatment: Chronic Obstructive Pulmonary Disease and Obesity is a manageable aspect of GLP-1 therapy that your provider can help you plan for from day one. The free FormBlends consultation covers your specific concerns, including how chronic obstructive pulmonary disease and obesity has been handled for patients in similar situations.

Track your experience: Note how chronic obstructive pulmonary disease and obesity changes week to week. This data helps your provider make better-informed decisions about dose adjustments and supportive strategies tailored to your response pattern.

How safe has semaglutide been across large obesity trials?

Semaglutide has been studied in over 20,000 patients across the STEP and SELECT trial programs. The most common side effects are GI-related (nausea, constipation, diarrhea) and are usually temporary. The SELECT trial showed a 20% reduction in cardiovascular[3] events, demonstrating a significant safety benefit.

What price should patients expect for semaglutide with and without coverage?

Brand Wegovy costs $1,300+/month without insurance. Compounded semaglutide ranges from $129-$349/month through telehealth providers. FormBlends compounded semaglutide starts at $99 for the first month, then $190 per month, or $165 per month with Subscribe & Save, with physician consultation and third-party purity testing included. Tirzepatide starts at $149 for the first month, then $239 per month, or $214 per month with Subscribe & Save.

Does semaglutide require a licensed prescriber first?

Yes. Semaglutide is a prescription medication that requires evaluation by a licensed healthcare provider. Telehealth platforms like FormBlends can prescribe after a medical consultation.

What happens to body weight after people stop semaglutide?

Semaglutide is considered a long-term treatment. The STEP 1 extension data showed weight regain after stopping. Most providers recommend ongoing treatment, potentially at a lower maintenance dose, for sustained results.

Using semaglutide with diabetes alongside COPD and obesity

Yes. Semaglutide (as Ozempic) is FDA-approved for type 2 diabetes. It improves blood sugar control and promotes weight loss. If you take insulin or sulfonylureas, your provider may need to reduce those doses to prevent low blood sugar.

What does telehealth compounded semaglutide typically cost per month?

Yes. FormBlends compounded semaglutide starts at $99 for the first month, then $190 per month, or $165 per month with Subscribe & Save, through state-licensed 503A compounding pharmacies with third-party purity testing on every batch. Physician consultations are included.

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
  2. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]

FormBlends compounded semaglutide starts at $99 for the first month, then $190 per month ($165 with Subscribe & Save), and tirzepatide starts at $149 for the first month, then $239 per month ($214 with Subscribe & Save), with physician consultations and third-party purity testing on every batch included. See current pricing or get started here.

Article sources: STEP 1 (NEJM 2021, DOI: 10.1056/NEJMoa2032183). Community data from 5,126 Reddit threads harvested March 2026.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →
What GLP-1 drugs do for COPD and obesity
FormBlends guide cover for What GLP-1 drugs do for COPD and obesity.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

What GLP-1 drugs do for COPD and obesity research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Download the First Month GLP-1 Checklist

A printable day-by-day checklist for your first month: what to eat, side effect management, and milestones.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

Patient Experience

GLP-1 for Chronic Liver Disease

GLP-1 for Chronic Liver Disease: patient experience guidance on patient experience, with safety context, decision points, and practical next steps.

Patient Experience

Thyroid Disease and Obesity: GLP-1 Considerations

Thyroid Disease and Obesity: GLP-1 Considerations: patient experience guidance on patient experience, with safety context, decision points, and...

Patient Experience

Autoimmune Disease and Obesity: GLP-1 Approach

Autoimmune Disease and Obesity: GLP-1 Approach: patient experience guidance on patient experience, with safety context, decision points, and practical...

Patient Experience

GLP-1 for Chronic Pain Patients

GLP-1 for Chronic Pain Patients: patient experience guidance on patient experience, with safety context, decision points, and practical next steps.

GLP-1 Weight Loss

GLP-1 for Chronic Kidney Disease: What the Research Shows

Comprehensive review of GLP-1 medications for chronic kidney disease. Explore how this drug class protects kidneys through hemodynamic, metabolic, and anti-inflammatory mechanisms.

Patient Experience

GLP-1 for Chronic Fatigue Syndrome and Weight

GLP-1 for Chronic Fatigue Syndrome and Weight: patient experience guidance on side effects and safety, with safety context, decision points, and...

Patient Experience

GLP-1 for Pulmonary Embolism Risk Reduction

GLP-1 for Pulmonary Embolism Risk Reduction: patient experience guidance on patient experience, with safety context, decision points, and practical...

GLP-1 Weight Loss

GLP-1 for Chronic Fatigue: What the Research Shows

Explore the evidence on GLP-1 medications for chronic fatigue. Learn how GLP-1 receptor agonists may address inflammation, metabolic dysfunction, and energy deficits in chronic fatigue syndrome.

Patient Experience

GLP-1 for Obstructive Sleep Apnea: Complete Guide

GLP-1 for Obstructive Sleep Apnea: Complete Guide: patient experience guidance on patient experience, with safety context, decision points, and...

FormBlends for iPhone

Track your routine in the FormBlends app

Doses, schedules, reminders, meals and progress in one free iPhone app.

Free Tools

Calculators to support your weight loss journey.